US2017340716A1PendingUtilityA1

Compositions and methods for the treatment of chronic obstructive pulmonary disease and asthma

53
Assignee: INDIANA UNIV RESEARCH & TECHNOLOGY CORPPriority: Apr 22, 2009Filed: Jun 19, 2017Published: Nov 30, 2017
Est. expiryApr 22, 2029(~2.7 yrs left)· nominal 20-yr term from priority
Inventors:David Wilkes
A61P 43/00A61P 37/02G01N 2800/56G01N 2333/78A61K 9/0053A61P 11/00G01N 2800/50G01N 2800/122G01N 2800/52G01N 33/6854A61K 39/0008A61P 11/08A61K 9/0019A61K 38/39A61P 11/06A61K 9/0073
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma.

Claims

exact text as granted — not AI-modified
1 .- 43 . (canceled) 
     
     
         44 . A method of treating or preventing chronic obstructive pulmonary disease (COPD) comprising administering to an individual afflicted with COPD or at risk of developing COPD a therapeutically effective amount of type V collagen. 
     
     
         45 . The method of  claim 44 , wherein the individual has emphysema or chronic obstructive bronchitis. 
     
     
         46 . The method of  claim 44 , wherein the therapeutically effective amount of type V collagen is administered to the individual by a route selected from the group consisting of oral administration, intravenous administration, intrapulmonary instillation, administration by inhalation, and intramuscular administration. 
     
     
         47 . The method of  claim 44 , wherein the therapeutically effective amount of type V collagen is between 0.5 mg and 1.0 mg per day. 
     
     
         48 . The method of  claim 44 , wherein the therapeutically effective amount of type V collagen is between 0.001 mg and 500 mg per day. 
     
     
         49 . The method of  claim 44 , wherein the therapeutically effective amount of type V collagen is between 0.01 and 5 mg per day. 
     
     
         50 . The method of  claim 44 , wherein the therapeutically effective amount of type V collagen is between 5.1 mg and 8.0 mg per day. 
     
     
         51 . The method of  claim 44 , wherein the therapeutically effective amount of type V collagen is administered daily as a single dose. 
     
     
         52 . The method of  claim 44 , comprising co-administering a bronchodilator. 
     
     
         53 . The method of  claim 44 , comprising co-administering a corticosteroid.

Join the waitlist — get patent alerts

Track US2017340716A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.